Understanding of leukemic stem cells and their clinical implications. Issue 1 (December 2017)

• Record Type: Journal Article
• Authors: Wang, Xuefei; Huang, Shile; Chen, Ji-Long
• Is Part Of: Molecular cancer. Volume 16:Issue 1(2017)
• Page Start: 1
• Page End: 10
• Publication Date: 2017-12
• Subjects: Cancer stem cell -- Leukemia -- Leukemic stem cell -- Surface markers -- BM niche -- ncRNAs -- Clinical implications; Cancer -- Molecular aspects -- Periodicals; 616.994
• DOI: 10.1186/s12943-016-0574-7
• Languages: English
• ISSNs: 1476-4598

Abstract

Abstract Since leukemic stem cells (LSCs) or cancer stem cells (CSCs) were found in acute myeloid leukemia (AML) in 1997, extensive studies have been contributed to identification and characterization of such cell populations in various tissues. LSCs are now generally recognized as a heterogeneous cell population that possesses the capacities of self-renewal, proliferation and differentiation. It has been shown that LSCs are regulated by critical surface antigens, microenvironment, intrinsic signaling pathways, and novel molecules such as some ncRNAs. To date, significant progress has been made in understanding of LSCs, leading to the development of numerous LSCs-targeted therapies. Moreover, various novel therapeutic agents targeting LSCs are undergoing clinical trials. Here, we review current knowledge of LSCs, and discuss the potential therapies and their challenges that are being tested in clinical trials for evaluation of their effects on leukemias.